German hospital operator Rhoen Klinikum, currently the target of a takeover bid by competitor Asklepios, looks set to part ways with its current CEO Stephen Holzinger.
A v-shaped recovery, new markets, new customers, new entrants, new technology and the ear of big government: the HBI 2020 diagnostics panel discussion reveals new opportunities.
European dental markets are reopening for business as R numbers drop below 1 across the continent. HBI reviews what the current position is in these key markets and talks to operators in these markets to assess demand.
Global real-estate investor PATRIZIA AG has acquired a portfolio of seven healthcare assets in Germany specialising in assisted living and specialist care in a sale & leaseback deal. Is this a good time to be investing in this sector in the light of the coronavirus pandemic? How is it affecting prices? HBI looks further at the deal and speaks to a consultant to find out more.
Oncology patients are among the most vulnerable in the current pandemic. Will that lead to more outmigration of therapies and increased use of hypofractionation? HBI speaks to operators in the France, Germany and the UK.
German and Spanish hospital operator Fresenius Helios has added €66m of sales in Germany with the acquisition of a hospital in Bonn from a non-profit organisation, its first domestic hospital deal in several years. We compare the finances of the for-profit and non-profit sectors with data exclusively provided to HBI by KPMG Germany.
Teleradiology providers across Europe have seen volumes crash for elective reads because of the shut down of non-essential work in public hospitals, while emergency reads have been less badly affected. But operators' low fixed costs should mean that profits will hold.
Regulatory body Public Health England (PHE) has ordered telehealth player Babylon to stop selling B2C antibody tests until it has established their accuracy. Supplier Abbott has already said that the test is not suitable for home sample collection but players are still scrambling to sell in what's likely to be a multi-billion market.
Ping An's early-stage investment arm Voyager Fund has invested in Berlin-based dental healthtech group PlusDental. We examine PlusDental's business model and talk to CEO Peter Baumgart who says demand has surged back in DACH.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
